Google NewsImugene (ASX:IMU): Biotech Stock Rockets as FDA Fast Track News Ignites Investor Excitement - Kalkine
Imugene (ASX:IMU): Biotech Stock Rockets as FDA Fast Track News Ignites Investor Excitement Kalkine
IMUGENE LIMITED ORDINARY (IMU) News
Latest articles and price-sensitive announcements with AI sentiment classification.
ASXAzer-cel Granted FDA Fast Track Designation for CLL and MZL
other announcement
azer-cel CAR-T naive data presented at ASCO Annual Meeting
other announcement
First Patient in BTKi Combination Cohort of azer-cel study
other announcement
KalkineImugene Advances Cancer Research With Azer-cel Progress
Highlights Azer-cel trial shows encouraging patient responses Study focuses on difficult blood cancer cases Imugene expands immunotherapy research momentum Imugene continues advancing its immuno-oncology pipeline as fresh clinical findings from its azer-cel study highlight encouraging treatment activity in difficult blood cancer cases. Clinical-stage immuno-oncology company Imugene (ASX:IMU) has drawn market attention after releasing fresh clinical findings linked to its azer-cel therap...
Azer-cel Data from CAR T naive cohort in ASCO 2026 abstract
other announcement
Change of Director's Interest Notice - PH
director_dealing announcement
Change of Director's Interest Notice - LC
director_dealing announcement
Notice under section 708A(12C)(e) of the Corporations Act
other announcement
Listed Options Top Holders & Holdings Range Report
other announcement
EGM Results and Share Purchase Plan Final Allotment
capital_raise announcement
Change of Director's Interest Notice -LC
director_dealing announcement
Imugene (ASX:IMU) Applies to List Shares After Conversions - kalkinemedia.com
Imugene (ASX:IMU) Applies to List Shares After Conversions kalkinemedia.com
Azer-cel data to be presented at 2026 ASCO Annual Meeting
other announcement
Notice of Extraordinary General Meeting/Proxy Form
other announcement
Imugene Capital Raise Drives Azer-Cel Cancer Program Forward
Highlights Imugene announces a major capital raising to advance its cancer therapy pipeline. Funds directed toward expansion of the azer-cel clinical program. New clinical cohorts and combination strategies planned in the next phase. Imugene Ltd has unveiled a significant funding initiative aimed at strengthening the development of its azer-cel therapy. The capital raise is designed to expand clinical trials and accelerate progress in innovative immunotherapy research. The announcement ...
$20M placement and SPP, convertible notes amended
capital_raise announcement
100% and 80% ORRs in Subset Indications in azer-cel study
other announcement
Imugene to Present at TD Cowen Annual Health Care Conference
other announcement